The Unethical Use of Placebo Controls

Karin B. Michels, Sc.D.
Harvard University

12 Noon, Friday, Jan. 30, 1998
VAMC Conference Room 207
(Research & Education Bldg., across from library)

Lunch will be provided

Placebo controls are still used in clinical trials in which an active treatment is approved and available and could be used as a control. The Declaration of Helsinki mandates that subjects in clinical trials receive the best available therapy. Yet government bodies as well as drug manufacturers demand placebo controls for Phase-III clinical trials. What motivates these apparently unethical requirements?

Dr. Michels teaches in the Department of Medicine at the Harvard Medical School and is Associate Epidemiologist at Brigham & Women’s Hospital.

Dialogues in Research Ethics is a series of monthly conferences. For more information about the series, phone 243-5723, write to Medical Campus Box M-825 or send E-mail to ethics@newssun.med.miami.edu

Sponsors:
- UM Forum for Bioethics & Philosophy
- Vice Provost & Deputy Dean for Research
- Department of Microbiology and Immunology
- Research Service of the Miami VAMC
- S. Florida VA Foundation for Research and Education
- Friends of the Forum for Bioethics